We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
IDEXX Laboratories, Inc (IDXX) is a leading diagnostics & research business with stocks listed in the US. It opened the day at US$539.23 after a previous close of US$541.08. During the day the price has varied from a low of USD538.65 to a high of USD554.1399. The latest price was USD546.26 (25 minute delay). IDEXX Laboratories is listed on the NASDAQ. All prices are listed in US Dollars.
How to buy shares in IDEXX Laboratories
- Compare share trading platforms. To buy shares in a US company from Australia you'll need to find a trading platform that offers access to US stock markets. If you're just starting out, look for a platform with low brokerage and foreign exchange fees.
- Open and fund your brokerage account. Complete an application with your personal and financial details, like your ID and tax file number. Fund your account with a bank transfer, credit card or debit card.
- Search for IDEXX Laboratories. Find the share by name or ticker symbol: IDXX. Research its history to confirm it's a solid investment against your financial goals.
- Purchase now or later. Buy today with a market order or use a limit order to delay your purchase until IDEXX Laboratories reaches your desired price. To spread out your risk, look into dollar-cost averaging, which smooths out buying at consistent intervals and amounts.
- Decide on how many to buy. At last close price of US$472.11, weigh your budget against a diversified portfolio that can minimise risk through the market's ups and downs. You may be able to buy a fractional share of IDEXX Laboratories, depending on your broker.
- Check in on your investment. Congratulations, you own a part of IDEXX Laboratories. Optimise your portfolio by tracking how your stock — and even the business — performs with an eye on the long term. You may be eligible for dividends and shareholder voting rights on directors and management that can affect your stock.
What's in this guide?
- IDEXX Laboratories key stats
- Compare share trading platforms
- Is IDEXX Laboratories stock a buy or sell?
- IDEXX Laboratories performance over time
- Can I short IDEXX Laboratories shares?
- Is IDEXX Laboratories suitable for ethical investing?
- Are IDEXX Laboratories shares over-valued?
- IDEXX Laboratories's financials
- How volatile are IDEXX Laboratories shares?
- Does IDEXX Laboratories pay a dividend?
- Have IDEXX Laboratories shares ever split?
- Other common questions
IDEXX Laboratories share priceUse our graph to track the performance of IDXX stocks over time.
IDEXX Laboratories shares at a glance
|52-week range||US$263.95 - US$573.99|
|50-day moving average||US$498.7774|
|200-day moving average||US$478.7162|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||US$6.71|
Compare share trading platforms to buy stock
Is it a good time to buy IDEXX Laboratories stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
IDEXX Laboratories price performance over time
|1 week (2021-04-13)||5.67%|
|1 month (2021-03-23)||12.02%|
Is IDEXX Laboratories under- or over-valued?
Valuing IDEXX Laboratories stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of IDEXX Laboratories's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
IDEXX Laboratories's P/E ratio
IDEXX Laboratories's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 81x. In other words, IDEXX Laboratories shares trade at around 81x recent earnings.
That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.
IDEXX Laboratories's PEG ratio
IDEXX Laboratories's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 6.7799. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into IDEXX Laboratories's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
IDEXX Laboratories's EBITDA
IDEXX Laboratories's EBITDA (earnings before interest, taxes, depreciation and amortisation) is US$790.5 million (£0.0 million).
The EBITDA is a measure of a IDEXX Laboratories's overall financial performance and is widely used to measure a its profitability.
IDEXX Laboratories financials
|Revenue TTM||US$2.7 billion|
|Operating margin TTM||25.66%|
|Gross profit TTM||US$1.6 billion|
|Return on assets TTM||21.04%|
|Return on equity TTM||143.63%|
|Market capitalisation||US$46.8 billion|
TTM: trailing 12 months
Shorting IDEXX Laboratories shares
There are currently 824,473 IDEXX Laboratories shares held short by investors – that's known as IDEXX Laboratories's "short interest". This figure is 3.5% down from 854,250 last month.
There are a few different ways that this level of interest in shorting IDEXX Laboratories shares can be evaluated.
IDEXX Laboratories's "short interest ratio" (SIR)
IDEXX Laboratories's "short interest ratio" (SIR) is the quantity of IDEXX Laboratories shares currently shorted divided by the average quantity of IDEXX Laboratories shares traded daily (recently around 505811.65644172). IDEXX Laboratories's SIR currently stands at 1.63. In other words for every 100,000 IDEXX Laboratories shares traded daily on the market, roughly 1630 shares are currently held short.
However IDEXX Laboratories's short interest can also be evaluated against the total number of IDEXX Laboratories shares, or, against the total number of tradable IDEXX Laboratories shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case IDEXX Laboratories's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 IDEXX Laboratories shares in existence, roughly 10 shares are currently held short) or 0.0109% of the tradable shares (for every 100,000 tradable IDEXX Laboratories shares, roughly 11 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against IDEXX Laboratories.
Find out more about how you can short IDEXX Laboratories stock.
IDEXX Laboratories's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like IDEXX Laboratories.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
IDEXX Laboratories's total ESG risk score
Total ESG risk: 29.79
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and IDEXX Laboratories's overall score of 29.79 (as at 12/31/2018) is nothing to write home about – landing it in it in the 55th percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like IDEXX Laboratories is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
IDEXX Laboratories's environmental score
Environmental score: 9.93/100
IDEXX Laboratories's environmental score of 9.93 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that IDEXX Laboratories is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
IDEXX Laboratories's social score
Social score: 14.44/100
IDEXX Laboratories's social score of 14.44 puts it squarely in the 6th percentile of companies rated in the same sector. This could suggest that IDEXX Laboratories is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
IDEXX Laboratories's governance score
Governance score: 17.91/100
IDEXX Laboratories's governance score puts it squarely in the 6th percentile of companies rated in the same sector. That could suggest that IDEXX Laboratories is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Environmental, social, and governance (ESG) summary
|Total ESG score||29.79|
|Total ESG percentile||54.84|
|Environmental score percentile||6|
|Social score percentile||6|
|Governance score percentile||6|
IDEXX Laboratories share dividends
We're not expecting IDEXX Laboratories to pay a dividend over the next 12 months.
Have IDEXX Laboratories's shares ever split?
IDEXX Laboratories's shares were split on a 2:1 basis on 15 June 2015. So if you had owned 1 share the day before before the split, the next day you'd have owned 2 shares. This wouldn't directly have changed the overall worth of your IDEXX Laboratories shares – just the quantity. However, indirectly, the new 50% lower share price could have impacted the market appetite for IDEXX Laboratories shares which in turn could have impacted IDEXX Laboratories's share price.
IDEXX Laboratories share price volatility
Over the last 12 months, IDEXX Laboratories's shares have ranged in value from as little as US$263.95 up to US$573.99. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while IDEXX Laboratories's is 0.8621. This would suggest that IDEXX Laboratories's shares are less volatile than average (for this exchange).
IDEXX Laboratories overview
IDEXX Laboratories, Inc. develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. The company operates through CAG; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. It provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and health monitoring, biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. The company also offers diagnostic and health-monitoring products for livestock, poultry, and dairy; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers and SARS-CoV-2 RT-PCR that are used in the human point-of-care medical diagnostics market; in-clinic chemistry, blood and urine chemistry, hematology, and SediVue Dx analyzers; SNAP rapid assays test kits. In addition, it provides Colilert, Colilert-18, and Colisure tests, which detect the presence of total coliforms and E. coli in water; Enterolert, Pseudalert, Filta-Max and Filta-Max xpress, Legiolert, and Quanti-Tray products; veterinary software and services for independent veterinary clinics and corporate groups. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was incorporated in 1983 and is headquartered in Westbrook, Maine.
Frequently asked questions
Ask an Expert